LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN) saw a significant increase in short interest in February. As of February 27th, there was short interest totaling 2,399,324 shares, an increase of 18.0% from the February 12th total of 2,032,704 shares. Approximately 4.4% of the company’s stock are sold short. Based on an average trading volume of 1,006,390 shares, the short-interest ratio is currently 2.4 days. Based on an average trading volume of 1,006,390 shares, the short-interest ratio is currently 2.4 days. Approximately 4.4% of the company’s stock are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. grew its stake in shares of LivaNova by 168.1% during the third quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock valued at $1,421,000 after buying an additional 17,007 shares during the last quarter. Allianz Asset Management GmbH bought a new position in LivaNova during the 3rd quarter worth approximately $7,687,000. LSV Asset Management increased its stake in LivaNova by 25.4% in the 3rd quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after purchasing an additional 136,600 shares during the period. Emerald Mutual Fund Advisers Trust lifted its position in LivaNova by 8.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock valued at $18,315,000 after purchasing an additional 26,202 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of LivaNova by 79.6% during the second quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after purchasing an additional 38,451 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a research report on Thursday, February 19th. KeyCorp started coverage on LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective for the company. Stifel Nicolaus set a $80.00 target price on LivaNova in a report on Wednesday, February 25th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $74.78.

LivaNova Price Performance

Shares of LivaNova stock traded up $0.56 on Wednesday, reaching $62.99. The stock had a trading volume of 399,820 shares, compared to its average volume of 787,993. The business’s 50 day moving average is $64.93 and its two-hundred day moving average is $59.86. The company has a market cap of $3.44 billion, a P/E ratio of -14.09 and a beta of 0.92. LivaNova has a 1 year low of $32.48 and a 1 year high of $71.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, research analysts anticipate that LivaNova will post 2.85 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.